MEPs join biotech sector to urge moving forward with Biotech Act II

Members of the European Parliament are joining forces with the biotech sector to urge the European Commission to move forward with the promised Biotech Act II – echoing earlier calls from biotech actors to act now. In a letter sent to Executive Vice President Stéphane Séjourné, lawmakers and the European Biosolutions Coalition stress that Biotech Act II is not optional. While the first Act focused on pharmaceuticals, the second is essential to unlock the full biotech ecosystem. Without it, cross‑sector barriers will continue to block biotech solutions from reaching the market and scaling across the Single Market. Delays only make Europe slower, not safer, the signatories warn. “We risk missing a major competitiveness opportunity” – one that Europe simply cannot afford.